Literature DB >> 29110586

Genetic variants of SULT1A1 and XRCC1 genes and risk of lung cancer in Bangladeshi population.

Tasnova Tasnim1,2, Mir Md Abdullah Al-Mamun1, Noor Ahmed Nahid1, Md Reazul Islam1, Mohd Nazmul Hasan Apu1, Most Umme Bushra1, Sikder Nahidul Islam Rabbi3, Zabun Nahar2, Jakir Ahmed Chowdhury4, Maizbha Uddin Ahmed1, Mohammad Safiqul Islam5, Abul Hasnat1.   

Abstract

Lung cancer is one of the most frequently occurring cancers throughout the world as well as in Bangladesh. This study aimed to correlate the prognostic and/or predictive value of functional polymorphisms in SULT1A1 (rs9282861) and XRCC1 (rs25487) genes and lung cancer risk in Bangladeshi population. A case-control study was conducted which comprises 202 lung cancer patients and 242 healthy volunteers taking into account the age, sex, and smoking status. After isolation of genomic DNA, genotyping was done by polymerase chain reaction-restriction fragment length polymorphism method and the lung cancer risk was evaluated as odds ratio that was adjusted for age, sex, and smoking status. A significant association was found between SULT1A1 rs9282861 and XRCC1 rs25487 polymorphisms and lung cancer risk. In case of rs9282861 polymorphism, Arg/His (adjusted odds ratio = 5.06, 95% confidence interval = 3.05-8.41, p < 0.05) and His/His (adjusted odds ratio = 3.88, 95% confidence interval = 2.20-6.82, p < 0.05) genotypes were strongly associated with increased risk of lung cancer in comparison to the Arg/Arg genotype. In case of rs25487 polymorphism, Arg/Gln heterozygote (adjusted odds ratio = 4.57, 95% confidence interval = 2.79-7.46, p < 0.05) and Gln/Gln mutant homozygote (adjusted odds ratio = 4.99, 95% confidence interval = 2.66-9.36, p < 0.05) were also found to be significantly associated with increased risk of lung cancer. This study demonstrates that the presence of His allele and Gln allele in case of SULT1A1 rs9282861 and XRCC1 rs25487, respectively, involve in lung cancer prognosis in Bangladeshi population.

Entities:  

Keywords:  Bangladeshi population; SULT1A1; XRCC1; lung cancer; pharmacogenomics; polymerase chain reaction–restriction fragment length polymorphism; polymorphism

Mesh:

Substances:

Year:  2017        PMID: 29110586     DOI: 10.1177/1010428317729270

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

1.  Potential Impact of Cancer Susceptibility Genes on Lung Cancer Metastasis.

Authors:  Jiaqing Wang; Bin Peng; Xuefeng Sun; Peikun Ding; Shixuan Li; Guofeng Li; Xiaoshun Shi; Guangsuo Wang
Journal:  J Oncol       Date:  2022-04-18       Impact factor: 4.501

Review 2.  SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Authors:  Katsuhisa Kurogi; Mohammed I Rasool; Fatemah A Alherz; Amal A El Daibani; Ahsan F Bairam; Maryam S Abunnaja; Shin Yasuda; Lauren J Wilson; Ying Hui; Ming-Cheh Liu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-06-30       Impact factor: 4.936

3.  Associations between three XRCC1 polymorphisms and hepatocellular carcinoma risk: A meta-analysis of case-control studies.

Authors:  Yao Xiong; Qian Zhang; Jiaxiang Ye; Shan Pan; Lianying Ge
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

4.  Evaluation of X-Ray Repair Cross-Complementing Family Members as Potential Biomarkers for Predicting Progression and Prognosis in Hepatocellular Carcinoma.

Authors:  Jie Mei; Huiyu Wang; Runjie Wang; Jiadong Pan; Chaoying Liu; Juanying Xu
Journal:  Biomed Res Int       Date:  2020-03-17       Impact factor: 3.411

5.  Structural and Dynamic Characterizations Highlight the Deleterious Role of SULT1A1 R213H Polymorphism in Substrate Binding.

Authors:  Raju Dash; Md Chayan Ali; Nayan Dash; Md Abul Kalam Azad; S M Zahid Hosen; Md Abdul Hannan; Il Soo Moon
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

6.  Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes.

Authors:  Magda Rybicka; Anna Woziwodzka; Alicja Sznarkowska; Tomasz Romanowski; Piotr Stalke; Marcin Dręczewski; Eloi R Verrier; Thomas F Baumert; Krzysztof Piotr Bielawski
Journal:  Cancers (Basel)       Date:  2020-11-07       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.